Straumann® XenoGraft and XenoFlex are biomaterials designed to eliminate antigenicity and provide a favourable environment for new bone growth. Available in a selection of practical containers for enhanced handling, its slow resorption increases stability, improving the likelihood of long-term implant survival rates.
Mastering everyday cases
Straumann® XenoGraft, for bone defect treatment, is methodically processed from bovine bone, extensively tested to eliminate antigenicity and provides a favourable environment for new bone growth. Its limited resorption rate delivers extended stability, a critical advantage in cases that require a strong framework for long-term tissue support or aesthetic needs.
Why Straumann® XenoGraft?
- Volume preservation by providing a long-lasting framework for excellent space maintenance (Fig. 1)
- Fast and straightforward application for optimal handling
- Innovative packaging for easy product handling and hydration
- Limited resorption rate provides extended stability
- Osteoconduction followed by organised integration and remodelling process (Fig. 2)
- Extended portfolio range
Straumann® XenoFlex is composed of 90% XenoGraft granules embedded in 10% purified porcine-derived collagen (type I). Straumann® XenoFlex is an optimal solution for graft applications required in extraction sockets and is available with a syringe applicator or as a block.
Why Straumann® XenoFlex?
- Efficient, easy to handle, volume stable: can be easily cut to match the size and shape of the individual defect after hydration
- It can be placed into the defect in one piece using tweezers, shortening surgery time
- Outstanding product stability after thorough hydration, supporting product application
- Extended block and cylinder shape portfolio
Versatile solutions for successful bone and tissue regeneration, Straumann® XenoGraft and XenoFlex are designed for the extraction sockets, sinus-floor elevation, horizontal augmentation, ridge preservation, peri-implant and intraosseous defects. Following the well-established treatment protocol using deproteinised bovine bone granules for the efficient treatment of bone defects, these biomaterials are easy to handle, have long-term volume stability and had been successfully applied in over 500,000 cases worldwide.
For more details, please visit: http://bit.ly/stmbiomaterial
Published in Dental Asia September/October 2021 issue.